ArticleCancer immunology research2020
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer immunology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 78 citations in OpenAlex.
- First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial.Signal transduction and targeted therapy · 2024Trial
- Analysis of cancer mutations introduced into theeLife · 2026Article
- Loss-of-Function Mutations in SWI/SNF Complexes Associated With Active Tumour Immune Microenvironment Clinical Response to Immune Checkpoint Blockade.Journal of cellular and molecular medicine · 2026Article
- Neoantigen Targeting as a Novel Approach for Therapy-Resistant Tumors.Molecular diagnosis & therapy · 2026Review
- Therapeutic misalignment averted by clonal evolutionary evidence: molecular confirmation of hepatic metastasis in SMARCA4-deficient non-small cell lung cancer initially misdiagnosed as resectable cholangiocarcinoma.Frontiers in oncology · 2026Article
- Article
- Clinicopathological and molecular perspectives on thoracic SMARCA4-deficient undifferentiated tumors and SMARCA4-deficient non-small cell lung carcinomas.Pathologica · 2025Review
- Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer.Cancer research · 2025Article
- Long-term survival of a SMARCA4-deficient undifferentiated thoracic tumor with brain metastasis successfully treated with multimodal treatment: a case report and literature review.Journal of cancer research and clinical oncology · 2025Review
- Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role ofJournal for immunotherapy of cancer · 2025Review
- Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.Cancer research · 2025Article
- Review
- Landscape of TET2 Mutations: From Hematological Malignancies to Solid Tumors.Cancer medicine · 2025Review
- Article
- Interferon response and epigenetic modulation byScience advances · 2024Article
- PHF10 inhibits gastric epithelium differentiation and induces gastric cancer carcinogenesis.Cancer gene therapy · 2024Article
- Actin like 6A is a prognostic biomarker and associated with immune cell infiltration in cancers.Discover oncology · 2024Article
- Deciphering glutamine metabolism patterns for malignancy and tumor microenvironment in clear cell renal cell carcinoma.Clinical and experimental medicine · 2024Article
- ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity.Cell · 2024Article
- SMARCA4 Mutations in Gastroesophageal Adenocarcinoma: An Observational Study via a Next-Generation Sequencing Panel.Cancers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 4 institutions in 4 countries.
Sarah Abou Alaiwi *Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Amin H Nassar *Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-8084-9105
Wanling XieDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
Ziad BakounyLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-1906-5704
Jacob E BerchuckLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-7607-2428
David A BraunLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sylvan C BacaLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Pier Vitale NuzzoLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-5618-8079
Ronan FlippotLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Tarek H MouhieddineDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-1190-5978
Liam F SpurrDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Yvonne Y LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Taiwen LiDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abdallah FlaifelLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-6705-018X
John A SteinharterLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Claire A MargolisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-1019-2419
Natalie I VokesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Heng DuDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Sachet A ShuklaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-2445-3584
Andrew D CherniackDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-0470-0111
Guru SonpavdeLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Robert I HaddadDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Mark M AwadLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Marios GiannakisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
F Stephen HodiMelanoma Center, Dana-Farber Cancer Institute, Boston, Massachusetts.
X Shirley LiuDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sabina SignorettiDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Cigall KadochDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
David J KwiatkowskiDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-5668-5219
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Toni K ChoueiriLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. toni_choueiri@dfci.harvard.edu.
Dana-Farber Cancer Institute · USBrigham and Women's Hospital · USInstitut Gustave Roussy · FRSichuan University · CN
Funding
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MRegulators of Cancer Immunotherapy ResponseR01CA234018 · NCI · DANA-FARBER CANCER INST · PI BROWN, MYLES A · 2019 to 2022
$2.3MNCI NIH HHS P50 CA101942NCI NIH HHS R01 CA234018
Abstract
Prior data have variably implicated the inactivation of the mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) complex with increased tumor sensitivity to immune checkpoint inhibitors (ICI). Herein, we examined the association between mSWI/SNF variants and clinical outcomes to ICIs. We correlated somatic loss-of-function (LOF) variants in a predefined set of mSWI/SNF genes (
Indexed as
MutationAdultAgedAged, 80 and overBiomarkers, TumorCohort StudiesDNA-Binding ProteinsDNA HelicasesHumansImmune Checkpoint InhibitorsMiddle AgedNeoplasmsNuclear ProteinsSMARCB1 ProteinSurvival RateTranscription FactorsARID1A protein, humanARID1B protein, humanARID2 protein, humanBiomarkers, TumorDNA-Binding ProteinsDNA HelicasesImmune Checkpoint InhibitorsNuclear ProteinsPBRM1 protein, humanSMARCA4 protein, humanSMARCB1 ProteinSMARCB1 protein, humanTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.